Article

Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.

F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Non-Clinical Safety, Basel, Switzerland.
European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences (Impact Factor: 2.61). 06/2012; 47(2):375-86. DOI: 10.1016/j.ejps.2012.06.013
Source: PubMed

ABSTRACT First pass metabolism in the intestinal mucosa is a determinant of oral bioavailability of CYP3A substrates and so the prediction of intestinal availability (Fg) of potential drug candidates is important. Although intestinal metabolism can be modeled in commercial physiologically based pharmacokinetic (PBPK) software tools, a thorough evaluation of prediction performance is lacking. The current study evaluates the accuracy and precision of GastroPlus Fg predictions for 20 CYP3A substrates using in vitro and in silico input data for metabolic clearance and membrane permeation, and illustrates a potential impact of intestinal metabolism modeling on decision making in a drug Research and Development project. This analysis supports that CYP3A mediated metabolic clearance measured in human liver microsomes can be used to predict gut wall metabolism. Using values scaled from in vitro cell permeability as input for effective jejunal permeability resulted in good Fg prediction accuracy (no significant bias and ∼95% of predictions within 2 fold from in vivo estimated Fg), whereas simulations with in silico predicted permeability tended to overestimate gut metabolism (40% of Fg predictions under predicted more than 2 fold) ±2 fold range as an estimate of imprecision in metabolic clearance and permeability inputs propagated to >5 and <2 fold ranges of predicted Fg for compounds with <30% and >75% in vivo Fg, respectively, suggesting lower precision of predictions for high extraction compounds. Furthermore, parameter sensitivity analysis suggests that limitations in solubility or dissolution may either decrease Fg by preventing saturation of metabolism or increase Fg by shifting the site of absorption towards the colon where expression of CYP3A is low. The case example illustrates how, when accounting for the associated uncertainty in predicted pharmacokinetics and linking to predictive models for efficacy, PBPK modeling of intestinally metabolized compounds can support decision making in drug Research and Development.

1 Bookmark
 · 
131 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Beagle dogs are used to study oral pharmacokinetics and guide development of drug formulations for human use. Since mechanistic insight into species differences is needed to translate findings in this species to human, abundances of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) drug metabolizing enzymes have been quantified in dog liver and intestine.
    Pharmaceutical research. 07/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to develop a sensitive and discriminative in vitro-in silico model able to simulate the in vivo performance of three fenofibrate immediate release formulations containing different surfactants. In addition, the study was designed to investigate the effect of dissolution volume when predicting the oral bioavailability of the formulations. In vitro dissolution studies were carried out using the USP apparatus 2 or a mini paddle assembly, containing 1000 or 100mL fasted state biorelevant medium, respectively. In silico simulations of small intestinal absorption where performed using the GI-Sim absorption model. All simulation runs were performed twice adopting either a total small intestinal volume of 533 or 105mL, in order to examine the implication of free luminal water volumes for the in silico predictions. For the tested formulations, the use of a small biorelevant dissolution volume was critical for in vitro-in silico prediction of drug absorption. Good predictions, demonstrating rank order in vivo-in vitro-in silico correlations for Cmax, were obtained with in silico predictions utilizing a 105mL estimate for the human intestinal water content combined with, solubility and dissolution data performed in a mini paddle apparatus with 100mL fasted state simulated media.
    International journal of pharmaceutics. 07/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Controlled release (CR) formulations are usually designed to achieve similar exposure (AUC) levels as the marketed immediate release (IR) formulation. However, the AUC is often lower following CR compared to IR formulations. There are a few exceptions when the CR formulations have shown higher AUC. This study investigated the impact of CR formulations on oral drug absorption and CYP3A4-mediated gut wall metabolism. A review of the current literature on relative bioavailability (Frel) between CR and IR formulations of CYP3A substrates was conducted. This was followed by a systematic analysis to assess the impact of the release characteristics and the drug-specific factors (including metabolism and permeability) on oral bioavailability employing a physiologically-based pharmacokinetic (PBPK) modelling and simulation approach. From the literature review, only three CYP3A4 substrates showed higher Frel when formulated as CR. Several scenarios were investigated using the PBPK approach; in most of them, the oral absorption of CR formulations was lower as compared to the IR formulations. However, for highly permeable compounds that were CYP3A4 substrates the reduction in absorption was compensated by an increase in the fraction that escapes from first pass metabolism in the gut wall (FG), where the magnitude was dependent on CYP3A4 affinity. The systematic simulations of various interplays between different parameters demonstrated that BCS class 1 highly-cleared CYP3A4 substrates can display up to 220% higher relative bioavailability when formulated as CR compared to IR, in agreement with the observed data collected from the literature. The results and methodology of this study can be employed during the formulation development process in order to optimize drug absorption, especially for CYP3A4 substrates.
    European Journal of Pharmaceutical Sciences 11/2014; 67:32. · 2.99 Impact Factor

Full-text

Download
15 Downloads
Available from
May 21, 2014